Lab21 is expanding its clinical diagnostics portfolio with the introduction of a new service to identify the two most common causes of fungal pneumonia. The CE-marked FXGTM:RESP (ASP+) test, developed by UK diagnostics company Myconostica, will identify infections caused by Aspergillus and Pneumocystis, which account for over 95% of cases of fungal pneumonia and could radically alter the diagnosis of fungal disease.
Launch Diagnostics is one of the major independent distributors in the U.K, providing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, France, Belgium, Netherlands, Luxemburg and North Africa and to the Republic of Ireland through ACCUSAY Diagnostics.
Liverpool Arena and Convention Centre
31 March - 3 April, 2025
Rome, Italy
10-11 April, 2025
Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025
Royal College Of Physicians Of Edinburgh
15 May, 2025
RAF Museum, Hendon, London NW9 5LL
15 May, 2025
